New hope for breast cancer patients: drug may prevent dangerous drop in blood cells during chemo
NCT ID NCT07647029
First seen Jun 16, 2026 · Last updated Jun 16, 2026
Summary
This study looks at whether the drug hetrombopag can help prevent low platelet counts (thrombocytopenia) caused by chemotherapy in breast cancer patients who are at high risk for this side effect. About 126 participants will be split into three groups: one getting no preventive drug, and two getting different schedules of hetrombopag. The goal is to see if the drug can reduce the chance of severe platelet drops and help patients complete their chemotherapy on time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.